Research Analysts Set Expectations for CRSP Q3 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Equities research analysts at Brookline Capital Management issued their Q3 2025 EPS estimates for CRISPR Therapeutics in a research report issued on Tuesday, February 11th. Brookline Capital Management analyst L. Cann expects that the company will earn ($0.94) per share for the quarter. The consensus estimate for […]

Leave a Reply

Your email address will not be published.

Previous post Amazon.com, Inc. (NASDAQ:AMZN) Shares Sold by Stablepoint Partners LLC
Next post CRISPR Therapeutics (NASDAQ:CRSP) Given “Buy” Rating at HC Wainwright